LongeVC managing partner Sergey Jakimov and operating partner Artem Trotsyuk co-wrote an opinion piece exploring how artificial intelligence is fundamentally restructuring drug discovery and personalized medicine. The article outlines how AI is compressing traditional decade-long development timelines into just a few years, with the healthcare AI market projected to reach $28 billion by 2025.
Jakimov and Trotsyuk argue that AI's real impact goes beyond efficiency gains; it's democratizing drug discovery by allowing small teams to explore complex aging-related pathways without billion-dollar budgets. They emphasize that while the opportunity is enormous, success requires rigorous validation and responsible scaling to build trust in algorithmic medicine.
Read the full op-ed here.
Jakimov and Trotsyuk argue that AI's real impact goes beyond efficiency gains; it's democratizing drug discovery by allowing small teams to explore complex aging-related pathways without billion-dollar budgets. They emphasize that while the opportunity is enormous, success requires rigorous validation and responsible scaling to build trust in algorithmic medicine.
Read the full op-ed here.